Skip to main content

Advertisement

SpringerLink
Log in

Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

During follow-up of acromegaly patients, there is a discordance rate of 30% between the measurements of growth hormone and insulin-like growth factor-1 levels. Further tests are required to determine disease activity in patients with discordant results. This study was planned to investigate an association of serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B with disease activity in acromegaly patients.

Methods

In this study, 64 acromegaly patients followed in our clinic were divided into two groups according to the 2010 consensus criteria for cure of acromegaly as patients with active disease (n = 24) and patients with controlled disease (n = 40). Serum matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B levels were measured by the enzyme-linked immunosorbent assay method.

Results

The mean serum matrix metalloproteinase-2 level was significantly higher in the active acromegaly patients than in the controlled acromegaly patients (150.1 ± 54.5 ng/mL vs. 100.2 ± 44.6 ng/mL; p < 0.0001). There was no significant difference between the active and controlled acromegaly patients regarding serum matrix metalloproteinase-9 and cathepsin B levels (p = 0.205 and p = 0.598, respectively). Serum matrix metalloproteinase-2 levels of 118.3 ng/mL and higher had a sensitivity of 75% and a specificity of 77.5% in determining active disease. The risk of active acromegaly was 3.3 fold higher in the patients with a matrix metalloproteinase-2 level of >118.3 ng/mL than in the patients with a matrix metalloproteinase-2 level of <118.3 ng/mL.

Conclusions

In this study, serum matrix metalloproteinase-2 level is increased in the active acromegaly patients and a threshold value in determining active disease was defined for serum matrix metalloproteinase-2 level. This study is the first to compare acromegaly patients having active or controlled disease in terms of matrix metalloproteinase-2 and matrix metalloproteinase-9 levels. The results need to be confirmed by a study that will be conducted in a larger patient group also including a healthy control group to demonstrate the value of this novel marker in disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. S. Melmed, Medical progress: acromegaly. N. Eng. J. Med. 355, 2558–2573 (2006)

    Article  CAS  Google Scholar 

  2. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Klienberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina; Acromegaly Consensus Group., guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009)

    Article  CAS  Google Scholar 

  3. E.O. Machado, G.F. Taboada, L.V. Neto, F.R. van Haute, L.L. Corrêa, G.A. Balarini, Y. Shrank, M. Goulart, M.R. Gadelha, Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth. Horm. IGF Res. 18, 389–393 (2008)

    Article  CAS  Google Scholar 

  4. I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol 159, 89–95 (2008)

    Article  CAS  Google Scholar 

  5. M.R. Farnoud, F. Farhadian, J.L. Samuel, P. Derome, F. Peillon, J.Y. Li, Fibronectin isoforms are differentially expressed in normal and adenomatous human anterior pituitaries. Int. J. Cancer 61, 27–34 (1995)

    Article  CAS  Google Scholar 

  6. K. Thapar, K. Kovacs, B.W. Scheithauer, L. Stefaneanu, E. Horvath, P.J. Pernicone, D. Murray, E.R. Laws Jr., Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38, 99–106 (1996)

    Article  CAS  Google Scholar 

  7. A. Page-McCaw, A.J. Ewald, Z. Werb, Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221–233 (2007)

    Article  CAS  Google Scholar 

  8. A. Nagase, R. Visse, G. Murphy, Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562–573 (2006)

    Article  CAS  Google Scholar 

  9. M.J. Duff, The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis. 10, 145–155 (1992)

    Article  Google Scholar 

  10. H. Kawamoto, T. Uozomi, K. Kawamoto, K. Arita, Y. Yano, T. Hirohata, Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir. (Wien). 138, 390–395 (1996)

    Article  CAS  Google Scholar 

  11. W. Liu, Y. Matsumoto, M. Okada, K. Miyake, K. Kunishio, N. Kawai, T. Tamiya, S. Nagao, Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J. Med. Invest. 52, 151–158 (2005)

    Article  Google Scholar 

  12. E. Beaulieu, Z. Kachra, N. Mousseau, L. Delbecchi, J. Hardy, R. Béliveau, Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45, 1432–1440 (1999)

    Article  CAS  Google Scholar 

  13. S. Yokoyama, H. Hirano, K. Moraki, M. Goto, S. Imamura, J.I. Kuratsu, Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 49, 857–862 (2001)

    CAS  PubMed  Google Scholar 

  14. U.J. Knappe, C. Hagel, B.W. Lisboa, W. Wilczak, D.K. Lüdecke, W. Saeger, Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol. 106, 471–478 (2003)

    Article  CAS  Google Scholar 

  15. M. Páez Pereda, M.F. Ledda, V. Goldberg, A. Chervín, G. Carrizo, H. Molina, A. Müller, U. Renner, O. Podhajcer, E. Arzt, G.K. Stalla, High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J. Clin. Endocrinol. Metab. 85, 263–269 (2000)

    PubMed  Google Scholar 

  16. J. Daroszewski, M. Bolanowski, M. Kaluzny, M. Siewinski, The imbalance of cathepsin B-like activity in acromegalic patients-preliminary report. Neuro. Endocrinol. Lett. 31, 256–260 (2010)

    CAS  PubMed  Google Scholar 

  17. A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed; Acromegaly Consensus Group., A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)

    Article  CAS  Google Scholar 

  18. K. Yoshimura, T. Tsuchida, K. Kawamoto, Expression of cathepsin B and cystatin C in the human adenohypophysis and in pituitary adenomas. Oncol. Rep. 7, 27–31 (2000)

    CAS  PubMed  Google Scholar 

  19. I. Berdowska, Cysteine proteases as disease markers. Clin. Chim. Acta 342, 41–69 (2004)

    Article  CAS  Google Scholar 

  20. A.N. Paisley, C.J. O’Callaghan, K.C. Lewandowski, C. Parkinson, M.E. Roberts, W.M. Drake, J.P. Monson, P.J. Trainer, H.S. Randeva, Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. J. Clin. Endocrinol. Metab. 91, 4635–4640 (2006)

    Article  CAS  Google Scholar 

  21. G.A. Kanakis, A. Chrisoulidou, A. Bargiota, L. Efstathiadou, A. Papanastasiou, A. Theodoropoulou, S.K. Tigas, D.A. Vassiliadi, S. Tsagarakis, M. Alevizaki, The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta analysis. Clin. Endocrinol. (Oxf). 85, 681–688 (2016)

    Article  CAS  Google Scholar 

  22. E.T. Cerit, K. Ağbaht, Ö. Demir, M. Şahin, V.T. Gedik, C. Özcan, D. Çorapçıoğlu, Discordance between GH and IGF-1 levels in Turkish acromegalic patients. Endocr. Pract. 22, 1422–1428 (2016)

    Article  Google Scholar 

  23. P.U. Freda, Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin. Endocrinol. (Oxf). 71, 166–170 (2009)

    Article  CAS  Google Scholar 

  24. H.J. Kim, S.H. Kwon, S.W. Kim, D.J. Park, C.S. Shin, K.S. Park, S.Y. Kim, B.Y. Cho, H.K. Lee, Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Horm. Res. 56, 117–123 (2001)

    CAS  PubMed  Google Scholar 

  25. M. Arosio, S. Garrone, P. Bruzzi, G. Faglia, F. Minuto, A. Barreca, Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein 1, -2, -3. J. Clin. Endocrinol. Metab. 86, 1091–1098 (2001)

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Biochemistry Department for laboratory measurements of research assays. The research was funded by Research Fund of Kocaeli University.

Author information

Authors and Affiliations

  1. Clinic of Endocrinology and Metabolism, Ankara Numune Training and Research Hospital, Ankara, Turkey

    Alper Cagri Karci

  2. Department of Endocrinology and Metabolism, Kocaeli University Faculty of Medicine, Kocaeli, Turkey

    Zeynep Canturk, Ilhan Tarkun & Berrin Cetinarslan

Authors
  1. Alper Cagri Karci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zeynep Canturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilhan Tarkun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Berrin Cetinarslan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alper Cagri Karci.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Medical Faculty of Kocaeli University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karci, A.C., Canturk, Z., Tarkun, I. et al. Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients. Endocrine 57, 148–155 (2017). https://doi.org/10.1007/s12020-017-1283-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-017-1283-8

Keywords

Search

Navigation